This trial is testing a new cancer drug combo to see if it's safe and effective against NSCLC and HR+ breast cancer.
2 Primary · 6 Secondary · Reporting Duration: Baseline to Date of Death Due to Any Cause (Approximately 18 Months)
Experimental Treatment
100 Total Participants · 4 Treatment Groups
Primary Treatment: Abemaciclib · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: